AstraZeneca (London, England) named David R. Brennan
as chief executive of North American operations. Brennan is an
executive director of AstraZeneca PLC and executive vice-president of
AstraZeneca North America. He is replacing retiring chief Tom McKillop.
Merck (Whitehouse Station, NJ) has shifted the responsibilities of several Management Committee members. Effective Sept. 1, Adel A.F. Mahmoud,
president of Merck Vaccines, will assume the new position of chief
medical advisor of vaccines and infectious diseases. Mahmoud, who is
scheduled for mandatory retirement from Merck in September 2006, will
continue to report to Richard T. Clark, CEO and president of Merck. Margaret G. McGlynn
will become president of Merck Vaccines, effective Sept. 1. McGlynn
will have global responsibilities for Merck's vaccines business,
including the oversight of the company's joint venture with
Sanofi-Aventis. For a full list of Merck's staff changes.(continued to Calendar)
